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Background: Chronic Obstructive Pulmonary Disease (COPD) is a chronic and progressive lung disease
characterized by irreversible airﬂow obstruction, airway inﬂammation, oxidative stress and, often, mucus
hypersecretion. The aim of this study is to determine if carbocisteine, a mucolytic and antioxidant agent,
administered daily for 12 months, can reduce exacerbation frequency in COPD patients.
Methods: This observational study was conducted in Naples (population approximately 1000,000), Italy.
It included 85 out-patients (mean age of 67.8 ± 8.6 years) followed by Clinic of Respiratory Diseases of
the University Federico II. Every patient underwent spirometry demonstrating airﬂow obstruction not
fully reversible according to ERS/ATS criteria for COPD diagnosis (Tiffenau index less than 70% after
administration of salbutamol, a beta2 agonist drug). Patients enrolled had diagnosed COPD since 2 years
and suffered at least one exacerbation in the previous year. None of the patients had been treated with
carbocisteine or other mucolytic agent for a longer period of time than 7 days and no more than 4 times
in the previous year to the enrollment. All of them assumed daily 2.7 g of carbocisteine lysine salt for a
year in addition to their basic therapy.
Results: The comparison of exacerbation frequency between the previous year (T0) and the end of study
treatment (T12), documents a statistically signiﬁcant reduction of exacerbations(number of exacerba-
tions at T0: 2 [1,3] vs number of exacerbations at T12: 1 [1,2]; p < 0.001).Quality of life was also reported
and showed a statistically signiﬁcant improvement at the end of the study (p < 0.001).We did not ﬁnd
correlation between reducing exacerbation frequency and exposure to cigarette smoking, passive
smoking exposure in childhood, the use of inhaled steroids, the level of education of our patients and the
GOLD stadium.
Interpretation: Daily administration of a mucolytic drug such as carbocisteine for prolonged periods in
addition to the bronchodilator therapy can be considered a good strategy for reducing exacerbation
frequency in COPD.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
Chronic Obstructive Pulmonary Disease (COPD), a term used to
describe progressive lung disease including bronchitis, emphysema
and the newly phenotypes “overlap COPD-asthma”, is a prevent-
able and treatable chronic respiratory disease associated with sig-
niﬁcant comorbidities and extrapulmonary effects that may
contribute to its severity. COPD is characterized by irreversible,sposito).persistent and progressive airﬂow obstruction related to airways
remodeling, mucus hypersecretion and breakage of alveolar septa
[1]. In addition to lung function decline, COPD patients have chronic
sputum, cough, and dyspnea [2]. These symptoms are particularly
evident after an exacerbation of COPD that is deﬁned as a sustained
worsening of the patient's condition, from the stable state and
beyond normal day-to-day variations, that is acute in onset and
may warrant additional treatment. Currently the disease is the
fourth leading cause of death andmorbidity worldwide imparting a
substantial economic burden on individuals and society. Recent
studies have also predicted that if current smoking trend continues,
by 2020 COPD will become the third cause of death worldwide
Table 1
Patient demographics and baseline characteristics.
Age, yr; mean ± std. dev 67.8 ± 8.6
Gender; n (%)
Female 19 (22.4)
Male 66 (77.6)
BMI; mean ± std. dev. 27.6 ± 4.8
Professional exposure/yes; n (%) 19 (47.5)
Smoking habit; n (%)
No smokers 10 (11.8)
Former smokers 39 (45.9)
Current smokers 36 (42.4)
Pack/Yr; median [25th e 75th percentile] 50 [40; 86.25]
Stage; n (%)
GOLD II 58 (69.3)
GOLD III 18 (20.9)
GOLD IV 9 (9.8)
Secondhand smoke; n (%)
No 27 (31.8)
Yes 58 (68.2)
Years from diagnosis; median [25the75th percentile] 4 [2,10]
COPD phenotype; n (%)
Emphysematous 38 (44.4)
Chronic bronchitis 47 (55.6)
BMI; median [25th e 75th percentile] 28 [24.8; 31]
Data are number (%) unless otherwise speciﬁed. COPD ¼ Chronic obstructive pul-
monary disease. GOLD ¼ Global Initiative for Chronic Obstructive Lung Disease.
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response to inhaled irritants, above all cigarettes smoking. The cells
responsible for the inﬂammatory response are mainly neutrophils
and macrophages [5]. In the smokers are involved cytotoxic T
lymphocytes and eosinophils too; the main role of this response is
carried out by inﬂammatory mediators such as chemotactic factors.
Oxidative stress due to high concentrations of free radicals released
by tobacco smoke and inﬂammatory cells is involved in pulmonary
damage too. Pulmonary epithelium, constantly exposed to toxic
exogenous pollutants inhaled and endogenous oxidants, undergoes
profound changes.
Lung, because of its big blood supply and the wide surface area,
is highly susceptible to oxidative stress [6]. In smokers and in COPD
patients, there is a small antioxidant capacity in plasma because of
the increased release of ROS (reactive oxygen species) by neutro-
phils and monocytes of peripheral blood and the reduction of
protein's sulﬁdrilic groups [7]. It was also recently reported that
antioxidants, such as glutathione, vitamin E and ascorbate, are
reduced in smokers and associated with the severity of exacerba-
tions of COPD [8]. From 2006, several Cochrane reviews that eval-
uated the effectiveness of drugs in the prevention of exacerbations
have been published. Mucolytic agents show a statistically signiﬁ-
cant reduction in exacerbation frequency and a decrease in the
number of disability days [9]; although this correlation was less
incisive in successive publications [10]. In any case, none of this
work had veriﬁed the effect of mucolytics for a long period of time.
Zheng et al. (2008) published a multicenter, randomized, placebo-
controlled study performed in China, which showed that a long-
term treatment (for 12 months) with carbocisteine associated
with long-acting and short-acting bronchodilator, anticholinergics
and inhaled steroids therapy was able to reduce exacerbation fre-
quency. This study also demonstrated that the effect on exacerba-
tions occurred regardless of the degree of disease severity, smoking
and use of inhaled steroids [11].
The purpose of our study is to verify how can change the
exacerbation frequency in a Caucasian population suffering from
COPD, during daily administration for 12 months of carbocisteine
lysine salt.
2. Methods
2.1. Patients
Participants were eligible for inclusion if theywere diagnosed as
having COPD with a post bronchodilator forced expiratory volume
in 1 s (FEV1) to forced vital capacity (FVC) ratio (FEV1/FVC) of less
than 0.70 and an FEV1 between 25% and 79% of predicted value. The
severity of COPD was deﬁned according to GOLD recommendations
[1]. At the end of run in period, we enrolled 89 COPD patients fol-
lowed at our clinic: Monaldi Hospital, Naples, southern Italy
(Table 1).
Besides, we divided our study population into two phenotypes,
predominant emphysema (n. 36, 44, 4%) and predominant chronic
bronchitis (n.45, 55,6%) according to both HRCT pattern and clinical
features.
Patients aged between 40 and 80 years, have a history of at least
1 COPD exacerbation within the previous year, both smokers and
non-smokers, women and men, with good oral and writing skills;
smoking status was recorded and veriﬁed by history. Our patients
were stratiﬁed into three groups, according to GOLD recommen-
dations (GOLD II 67.4%; GOLD III 21%; GOLD IV 11.6%) [1].
Patients were excluded if they had limited mobility, neoplastic
diseases, diffuse bilateral bronchiectasis, psychiatric disorders,
transplant, systemic diseases with pulmonary involvement, known
or suspected hypersensitivity to the study medication or part of itsingredients, treatment with carbocisteine for a longer period of 7
days and more than 4 cycles and involvement in an investigational
drug trial in the previous 12 months. We monitored previous year
exacerbation frequency by administering a clinical diary where the
patient pinned any exacerbations. None of patients used oral
corticosteroids, alcohol or drugs. Participants have all signed free
informed consent. The study was approved by local ethics
committees.
2.2. Study design
CAPRI (Carbocysteine in Prevention of exaceRbation of COPD) is
an observational and prospective study. Enrolled patients were
treated with daily administration of 2.7 g/day carbocysteine lysine
salt equivalent to 1.5 g/day carbocysteine (1 packet of granules for
oral solution/day). The patients were examined every threemonths
until the end of the study to assess the vital signs, record any ex-
acerbations, adverse events, and to verify their adherence to the
study regimen. At baseline, demographic and anthropometric pa-
rameters, age, sex, weight, height, hypertension, pulse, medical
history, diseases/concomitant medications, history of smoking
status and exposure passive smoking in childhood, were collected.
We also recorded the date of COPD diagnosis, COPD features,
spirometry (TLC, FEV 1, FVC), arterial blood gas analysis (EGA),
6-min walking test (6MWT) and administered to each participant
two questionnaires to investigate the quality of life: the COPD
Assessment Test (CAT) and the St. George's Respiratory
Questionnaire (SGRQ), designed and validated by PW Jones, of St
George's Hospital Medical School, in its Italian version [12].
At each checkup, 3, 6, 9 months, current therapy, exacerbation
frequency and the eventual treatment was recorded. New
spirometry (FEV 1, FVC, TLC) and EGA were performed. The
adherence to current treatment with conﬁrmation/amendment if
needed and assessment of adverse events were veriﬁed. We made
the ﬁnal visit after 12 months or previously in case of early
termination of the study. In this particular case, exacerbation fre-
quency and any treatment related and adverse events were
assessed. A last spirometry (FEV1, FVC, TLC) and EGA examination,
as well as a 6MWT, SGRQ and CAT were performed. Conventional
treatment for COPD, short- and long-acting bronchodilator and
Table 2
Number of Exacerbations and Quality of Life improvement described by median [25
the75th percentile].
T0 T12 p
Nr. of Exacerbations 2 [1; 3] 1 [1; 2] <0.001
St. George Symptoms 56 [42.5; 70] 42 [20.5; 55] <0.001
St. George Activity 72 [59; 89.5] 60 [45; 80] <0.001
St. George Impacts 47 [29; 60.5] 36 [15; 56.5] <0.001
St. George Total 58 [42.5; 70] 45 [25.5; 62.5] <0.001
CAT 19 [12; 25] 17 [10; 23] <0.001
6MWT (mt) 396 [352; 440] 418 [352; 484] <0.001
Fig. 1. Graphic representation of improvement of quality of life.
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administration of corticosteroids, antibiotics, mucolytic or anti-
tussive were permitted just for the treatment of exacerbations.
2.3. Outcomes
The primary endpoint was exacerbation rate over 1 year of
carbocisteine treatment compared with the previous year without
carbocysteine therapy. Exacerbation was deﬁned according to
Anthonisen criteria: persistence for a minimum of 2 days of at least
two major symptoms (increased dyspnea and increased sputum
volume or purulence) or one major plus one more minor symptom
(infection of the upper airways, increased wheezing or unexplained
fever) [13].
Secondary endpoints included the evaluation of other parame-
ters analyzed during the study: 6MWT, Bode index, EGA, PFR. The
evaluation of quality of life was made comparing each SGRQ at the
end of treatment with the one at baseline, thus each patient acted
as the control of himself [14].
The correlation between the reduction of exacerbations and
exposure to secondhand smoking in pediatric age, the severity of
COPD according to the GOLD stage, the use of inhaled corticoste-
roids, the level of education and occupational exposure to harmful
substances were investigated as well.
Because the aim of the present study was to value the role of
carbocisteine as antioxidant rather than mucolytic agent, we didn't
register sputum amount or its purulence.
2.4. Statistical analysis
A sample size of 77 subjects was required to detect a reduction
in the mean number of exacerbation per year equal to 0.5 assuming
a standard deviation of the differences equal to 1.5 (effect size equal
to 0.33) with a power of 80% and a two sided signiﬁcance level of
0.05. The number of patients was then increased by 15% in order to
account for the non normal distribution of the primary outcome
variable.
Numerical variables were described by median [25th e 75th
percentile], while categorical variables were summarized through
absolute frequencies and percentages. Treatment effect on longi-
tudinal variations of the primary outcome in the whole study
sample was assessed using the nonparametric Wilcoxon test and
then compared between the COPD phenotypes using the Mann
Whitney test. The time trend of the variables number of exacer-
bations” and “BODE index” was later dichotomized separating the
subjects with improvement in the follow-up (fewer exacerbations
and reduction of BODE index from baseline) by those without
improvement. The subgroups so obtained were compared (Mann
Whitney test for numerical variables and Fisher's exact test for
categorical variables) in order to identify potential factors associ-
ated with improvement. All statistical tests were two-tailed, and p
values less than 0.05 were considered statistically signiﬁcant. It was
not undertaken to adjust the analysis for multiple comparisons.
The analyzes were performed using SPSS statistical software
vers.20.
3. Results
The study population was analyzed at the end of the study
period (T12) of daily administration of carbocisteine. 4 patients
were lost in follow-up: 2 because of gastrointestinal disorders
related to the drug, 1 suffered hemoptysis due to a recently
discovered lung cancer and 1 because of poor adherence to therapy.
Other patients reported mild side effects that have not compro-
mised the study because they didn't required the discontinuation oftreatment.
The analysis of the study, reveals that there is a statistically
signiﬁcant reduction in the exacerbation frequency compared to
previous year (median exacerbations at T0: 2 [1,3] vs at T12: 1 [1,2];
p < 0.001) (Table 2).
This reduction is more signiﬁcant in the “chronic bronchitis
phenotype” (40 patients, 85,1%) than “emphysematous” pheno-
type, (7 patients, 14.9%) (p < 0.001).
A statistically signiﬁcant increase of the distance in meters
walked (6MWT) (distance in meters T0: 396 [352; 440] vs T12: 418
[356; 484]; p < 0.001) was observed in T12 as well. The distance in
meters to 6 MWT is one of the items of the BODE Index, an
important prognostic index for COPD patients, also improved in T12
(BODE INDEX T0: 1 [0.5; 3] vs T12 [0; 2]; p < 0.001) (Table 2).
The comparison of results of tests of the quality of life at baseline
and at the end of the study showed a statistically signiﬁcant
improvement in quality of life in the study population, both with
the items of SGRQ (activity, symptoms and impact) and the sum of
all these (p < 0.001), both with CAT (p < 0.001) (Fig. 1).
The association between exacerbation frequency reduction and
disease severity, after treatment, according to GOLD stage, was not
statistically signiﬁcant (Table 3).
The reduction of exacerbation frequency did non correlate with
active or passive exposure to cigarette smoking, use of inhaled
steroids, exposure to occupational pollutants and level of education
of the patients.
4. Discussion
The results of our study demonstrate that the daily use of car-
bocisteine, administered for twelve consecutive months, signiﬁ-
cantly reduces the number of exacerbations (p < 0.001). The
primary end point was reached after 12months of therapy whereas
the PEACE study achieved the same result in six months [11]. Poole
Table 3
Association between exacerbation frequency reduction and disease severity, after
treatment, according to GOLD stage.
Gold stage
at baseline
More or equal
exacerbations (n ¼ 34)
Less exacerbations
(n ¼ 47)
p
II 21 (61.8) 35 (74.5) 0.082
III 11 (32.4) 6 (12.8)
IV 2 (5.9) 6 (12.8)
Table 4
Side effects of carbocisteine in our population.
N ¼ 85
Gastrointestinal disorders 4
Headache 2
Hemoptysis 1
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a total of 7335 participants in treatment withmucolytic drugs for at
least two months documented a signiﬁcant reduction in exacer-
bation frequency. But, subsequently, further contributions in the
literature suggested different results and the recommendations for
the use of mucolytic drugs in addition to the basic therapy in COPD
to reduce the number of exacerbations and improve quality of life,
lost power [10,15e17].
Our results, instead, seem to support this recommendation, and
considering the very low number of adverse events recorded and
the good tolerability (Table 4) suggest to extend the administration
of the drug for at least 12 months.
An important point of our study is that the cut in exacerbation
frequency in our patients was completely independent from the
use of inhaled corticosteroids. This ﬁnding differs from the BRON-
CUS study, in which N-acetylcysteine was used as mucolytic agent
[18]. Among the secondary end points, there is an improvement in
the quality of life assessed by a statistically signiﬁcant decrease in
SGRQ score, according to the PEACE study [11]. A signiﬁcant
improvement in lung function (FEV1, FVC, FEV1/FVC), as expected
and in agreement with other similar studies was not achieved.
However, a signiﬁcant increase of the distance walked (6MWT)
and, consequently, a signiﬁcant reduction in the BODE index were
observed. The improvement of BODE index is very important, being
the BODE a more predictive parameter than FEV1 about the risk of
mortality from general cause and from respiratory causes in pa-
tients with COPD [19].
5. Conclusions
Oxidative stress is a key point in the pathogenesis of COPD. For
this reason, to act on oxidative stress both with pharmacological
antioxidants and by increasing endogenous levels of oxidants, is
today an important target in the treatment and management of
COPD. Carbocisteine is a mucolytic drug with anti-inﬂammatory
and antioxidant action and this latter effect may be what led to
the achievement of the results reported. Another interesting aspect
of carbocisteine is its supposed ability to modulate the function of
epithelial cells of the lining of the airways, including the expression
of ICAM1a, which is a receptor for the rhinovirus pathogens most
commonly implicated in the genesis of the cold. Therefore, thismolecule could play a very important role for the long-term
treatment of patients with COPD and it is for this reason that in
recent years has attracted considerable interest. In spite of that,
mucolytic agents, althoughwidely used in clinical practice for short
periods, are not currently recommended by the GOLD recommen-
dations (Evidence D) [1]. Our results, although have to be supported
by other similar studies, seem to be in favor of the long term use of
these drugs as powerful antioxidant agents capable to contribute to
improve the management of COPD patients.References
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